Development of Cell-Cycle Inhibitors for Cancer Therapy

• DOI: 10.3747/co.v16i2.428
• Publication Date: 2009-03-25T19:22:52Z
• Authors: M. A. Dickson; Gary K. Schwartz
• Keywords: Palbociclib

The cell cycle governs the transition from quiescence through growth to proliferation. key parts of machinery are cyclin-dependent kinases (cdks) and regulatory proteins called cyclins. cdks rational targets for cancer therapy because their expression in cells is often aberrant inhibition can induce death. Inhibitors also block transcription. Several drugs targeting have entered clinical trials. These agents include flavopiridol, indisulam, AZD5438, SNS-032, bryostatin-1, seliciclib, PD 0332991, SCH 727965. Phase i studies demonstrated that these generally be administered safely. ii shown little single-agent activity solid tumors, but combination with cytotoxic chemotherapy been more promising. In hematologic malignancies, reports encouraging activity. Pharmacodynamic show dose schedule crucial permit maximum therapeutic effect.